Arf-dependent regulation of Pdgf signaling in perivascular cells in the developing mouse eye

EMBO Journal

Volumn 24, Issue 15, 2005, Pages 2803-2814

  Silva, Ricardo L A ^a   Thornton, J Derek ^a   Martin, Amy C ^a   Rehg, Jerold E ^a   Bertwistle, David ^a   Zindy, Frederique ^a   Skapek, Stephen X ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Eye development; p19Arf; Pericytes; Platelet derived growth factor; Tumor suppressor gene

Indexed keywords

ARF PROTEIN; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN MDM2; PROTEIN P19; PROTEIN P53;

ALLELE; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL PROLIFERATION; EMBRYO; EMBRYO CELL; EYE DEVELOPMENT; MITOGENESIS; MOUSE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; VITREOUS BODY;

ANIMALS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EYE; MICE; MICE, KNOCKOUT; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; PROTO-ONCOGENE PROTEINS C-SIS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 23844516784     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.emboj.7600751     Document Type: Article

References (50)

1. Beck Jr L, D'Amore PA (1997) Vascular development: cellular and molecular regulation. FASEB 11: 365-373
2. Benjamin LE, Golijanin D, Itin A, Pode D, Kesher E (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103: 159-165
3. Benjamin LE, Memo I, Keshet E (1998) A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125: 1591-1598
4. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111: 1287-1295
5. Bertwistle D, Zindy F, Sherr CJ, Roussel MF (2004) Monoclonal antibodies to the mouse p19Arf tumor suppressor protein. Hybridoma Hybridomics 23: 293-300
6. ARF tumor suppressor. Genes Dev 12: 2434-2442
7. Della TG, Pasini B, Frigerio S, Donghi R, Rovini D, Delia D, Peters G, Huot TJ, Bianchi-Scarra G, Lantieri F, Rodolfo M, Parmiani G, Pierotti MA (2001) CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation. Br J Cancer 85: 836-844
8. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS, Bradley A (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221
9. Gee MS, Procopio WN, Makonnen S, Feldman MD, Yeilding NM, Lee WM (2003) Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol 162: 183-193
10. Gerhardt H, Betsholtz C (2003) Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 314: 15-23
11. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C (2003) VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161: 1163-1177
12. Hackzell A, Uramoto H, Izumi H, Kohno K, Funa K (2002) p73 independent of c-Myc represses transcription of platelet-derived growth factor beta-receptor through interaction with NF-Y. J Biol Chem 277: 39769-39776
13. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364
14. Hellstrom M, Gerhardt H, Kalen M, Li X, Eriksson U, Wolburg H, Betsholtz C (2001) Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 153: 543-553
15. Hellstrom M, Kalen M, Lindahl P, Abramsson A, Betsholtz C (1999) Role of PDGF-B and PDGFR-β in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126: 3047-3055
16. Hewitt C, Wu CL, Evans G, Howell A, Elles RG, Jordan R, Sloan P, Read AP, Thakker N (2002) Germline mutation of ARF in a melanoma kindred. Hum Mol Genet 11: 1273-1279
17. Hirschi KK, Rohovsky SA, D'Amore PA (1998) PDGF, TGF-β, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J Cell Biol 141: 805-814
18. Hoch RV, Soriano P (2003) Roles of PDGF in animal development. Development 130: 4769-4784
19. Ikeda S, Hawes NL, Chang B, Avery CS, Smith RS, Nishina PM (1999) Severe ocular abnormalities in C57BL/6 but not in 129/Sv p53-deficient mice. Invest Ophthalmol Vis Sci 40: 1874-1878
20. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA (1994) Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1-7
21. Jain RK, Booth MF (2003) What brings pericytes to tumor vessels? J Clin Invest 112: 1134-1136
22. Kamijo T, Bodner S, van de Kamp E, Randle DH, Sherr CJ (1999) Tumor spectrum in ARF-deficient mice. Cancer Res 59: 2217-2222
23. ARF. Cell 91: 649-659
24. Leveen P, Pekny M, Gebre-Medhin S, Swolin B, Larsson E, Betsholtz C (1994) Mice deficient for PDGF b show renal, cardiovascular, and hematological abnormalities. Genes Dev 8: 1875-1887
25. Lindahl P, Johansson BR, Leveen P, Betsholtz C (1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277: 242-245
26. Lindblom P, Gerhardt H, Liebner S, Abramsson A, Enge M, Hellstrom M, Backstrom G, Fredriksson S, Landegren U, Nystrom HC, Bergstrom G, Dejana E, Ostman A, Lindahl P, Betsholtz C (2003) Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev 17: 1835-1840
27. Martin AC, Thornton JD, Liu J, Wang XF, Zuo J, Jablonski MM, Chaum E, Zindy F, Skapek SX (2004) Pathogenesis of persistent hyperplastic primary vitreous in mice lacking the Arf tumor suppressor gene. Invest Ophthalmol Vis Sci 45: 3387-3396
28. McKeller RN, Fowler JL, Cunningham JJ, Warner N, Smeyne RJ, Zindy F, Skapek SX (2002) The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development. Proc Natl Acad Sci USA 99: 3848-3853
29. Mitchell CA, Risau W, Drexler HC (1998) Regression of vessels in the tunica vasculosa lentis is initiated by coordinated endothelial apoptosis: a role for vascular endothelial growth factor as a survival factor for endothelium. Dev Dyn 213: 322-333
30. Orlidge A, D'Amore PA (1987) Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. J Cell Biol 105: 1455-1462
31. Ozerdem U, Grako KA, Dahlin-Huppe K, Monosov E, Stallcup WB (2001) NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. Dev Dyn 222: 218-227
32. ARF links the tumor suppressor p53 to Ras. Nature 395: 127
33. Pavel S, Smit NP, van der MH, Kolb RM, de Groot AJ, van d, V, Gruis NA, Bergman W (2003) Homozygous germline mutation of CDKN2A/p16 and glucose-6-phosphate dehydrogenase deficiency in a multiple melanoma case. Melanoma Res 13: 171-178
34. Qi Y, Gregory MA, Li Z, Brousal JP, West K, Hann SR (2004) p19Arf directly and differentially controls the functions of c-Myc independently of p53. Nature 431: 712-717
35. Randerson-Moor JA, Harland M, Williams S, Cuthbert-Heavens D, Sheridan E, Aveyard J, Sibley K, Whitaker L, Knowles M, Bishop JN, Bishop DT (2001) A germline deletion of p14Arf but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 10: 55-62
36. Reichel MB, Ali RR, D'Esposito F, Clarke AR, Luther PJ, Bhattacharya SS, Hunt DM (1998) High frequency of persistent hyperplastic primary vitreous and cataracts in p53-deficient mice. Cell Death Differ 5: 156-162
37. Rocha S, Campbell KJ, Perkins ND (2003) p53- and Mdm2-independent repression of NF-KB transactivation by the ARF tumor suppressor. Mol Cell 12: 15-25
38. Sato Y, Rifkin DB (1989) Inhibition of endothelial cell movement by preicytes and smooth muscle cells: activation of a latent transforming growth factor-β1-like molecule by plasmin during coculture. J Cell Biol 109: 309-315
39. Sherr CJ (1998) Tumor surveillance via the ARF-p53 pathway. Genes Dev 12: 2984-2991
40. Sims DE (1986) The pericyte-a review. Tissue Cell 18: 153-174
41. Soriano P (1994) Abnormal kidney development and hematological disorders in PDGF b-receptor mutant mice. Genes Dev 8: 1888-1896
42. Sugimoto M, Kuo M-L, Roussel MF, Sherr CJ (2003) Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol Cell 11: 415-424
43. Syljuasen RG, Krolewski B, Little JB (2001) Molecular events in radiation transformation. Radiat Res 155: 215-221
44. Vaziri C, Faller DV (1995) Repression of platelet-derived growth factor β-receptor expression by mitogenic growth factors and transforming oncogenes in murine 3T3 fibroblasts. Mol Cell Biol 15: 1244-1253
45. Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel MF, Sherr CJ, Zambetti GP (2000) p53-independent functions of the p19Arf tumor suppressor. Genes Dev 14: 2358-2365
46. Yakobson E, Shemesh P, Azizi E, Winkler E, Lassam N, Hogg D, Brookes S, Peters G, Lotem M, Zlotogorski A, Landau M, Safro M, Shafir R, Friedman E, Peretz H (2000) Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families. Eur J Hum Genet 8: 590-596
47. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248
48. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12: 2424-2433
49. Zindy F, Quelle DE, Roussel MF, Sherr CJ (1997) Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15: 203-211
50. Zindy F, Williams RT, Baudino TA, Rehg JE, Skapek SX, Cleveland JL, Roussel MF, Sherr CJ (2003) Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc Natl Acad Sci USA 100: 15930-15935